Jiangnan University

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Shanghai Institute of Pharmaceutical Industry

Iview Therapeutics, Inc.

Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd.

Wei Song

Hongjiang Xu

Xiulai Chen

Xiquan Zhang

Liming Liu

Jia Liu

Ling Yang

Ying Zhang

Jing Wu

Cong Gao

Qiuling Luo

Liang Guo

Shanchun Wang

Bo Liang

Zhedong Yuan

Xiaomin Zhang

Xueyan Zhu

Ping Dong

Wei Shi

Hao Yu

Hubo Wang

Hongmei Gu

Xingfeng Ge

Dandan Lu

Zhongnan Xu

Hui Fu

Kai Zheng

Wenxiu Tang

Chen Shen

Mincheng Zhang

Joseph A Capriotti

Michael C Samson

Zhilan Zhang

Belachew Tessema

Lei Huang

Zhongying Sun

Deyang Chen

Shanshan Pei

Xin Xu

The present invention provides recombinantfor producing glutarate, a construction method and use thereof. A double-plasmid recombinant bacterium is constructed through molecular biological means for co-expressing an aldehyde synthase (AAS) gene, an amine oxidase Mao (gene) and an aldehyde dehydrogenase (Glox) gene. The constructed expression plasmids are introduced into theto reconstruct to obtain recombinant cells. A recombination strain for efficiently producing glutarate is obtained through amicillin resistance and kanamycin resistance combined plate screening. Efficient production of the glutarate is achieved by optimizing concentration of a substrate, cell concentration and a transformation temperature. L-lysine with a concentration of 30 g/L may be transformed into 19.65 g of glutarate through reactions for 30 h under transformation conditions that the cell concentration is 30 g/L, the pH value is 8 and 6 mM of NADis additionally added, wherein a transformation rate may be 65.3%.

Recombinantfor producing glutarate, construction method and use thereof

A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.

Drug combination containing TLR7 agonist

Disclosed is an acid phosphatase mutant obtained fromhaving the amino acid sequence of SEQ ID NO:3 and method of using the mutant in the technical field of biological engineering. The disclosure provides a mutant of acid phosphatase PaAPase. By expressing the mutant of acid phosphatase PaAPaseinand using a whole-cell conversion method, L-ascorbic acid is transformed into L-ascorbate-2-phosphate. Moreover, the problems of a high substrate cost, environmental pollution and the like are greatly reduced, laying a foundation for the industrial green production of L-ascorbate-2-phosphate.

Acid phosphatase mutants and methods of using the same

Disclosed are a compound of formula I as a toll-like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating colorectal cancer, a pharmaceutical combination for treating colorectal cancer comprising the TLR7 agonist and a tyrosine kinase inhibitor, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating colorectal cancer.

TLR7 agonist for treating colorectal cancer and pharmaceutical combination thereof

The present application relates to a compound of formula I as a toll-Like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating lung cancer, a pharmaceutical combination of the TLR7 agonist and a tyrosine kinase inhibitor for treating lung cancer, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating lung cancer.

TLR7 agonist and pharmaceutical combination thereof for treating lung cancer

The present invention provides pharmaceutical compositions comprising an iodine-containing compound and a steroid, useful for treating a clinical symptom in a patient's airway (e.g., nose, lung, and sinus), as well as methods for using the same.

Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases

The invention provides a recombinantstrain for producing succinic acid and a construction method thereof. The by-product encoding genes in thestrain FMME-N-2 are knocked out to obtain thestrain FMME-N-5 (ΔfocA-pflB-ΔldhA-Δpta-ackA); and the phosphoenolpyruvate carboxykinase pck derived fromand the phosphite dehydrogenase ptxD derived fromwere overexpressed. The constructed plasmid pTrcHisA-pck-ptxD was introduced into the expression hostFMME-N-5 (ΔfocA-pflB-ΔldhA-Δpta-ackA), and the cells were screened in a plate containing ampicillin, to obtain an engineered strainFMME-N-5 (ΔfocA-pflB-ΔldhA-Δpta-ackA)-pck-ptxD that can efficiently produce succinic acid. After fermentation by a two-stage fermentation strategy, the production of succinic acid reaches 137 g/L, the yield of succinic acid is up to 1 g/g glucose, and the space time yield is 1.43 g/L/h, while no by-products of lactic acid and formic acid are accumulated, and the acetic acid content is 1-2 g/L.

Recombinantstrain for producing succinic acid and construction method thereof

The disclosure discloses preparation of an L-amino acid deaminase mutant and application thereof, belonging to the technical field of gene engineering. Through pmirLAAD protein modification, analysis of a flexible loop structure around a binding site of the pmirLAAD product, and design of the best mutant, the modification method of the disclosure overcomes the defect that the catalytic efficiency of the previous wild-type enzyme is reduced due to product inhibition, and is tested by experiments. Compared with the control, the catalytic efficiency (1.61 mM&#xb7;min) and the product inhibition constant (5.4 mM) of the finally obtained best mutant pmirLAADare respectively increased by 5.2 times and 5.7 times. The yield of &#x3b1;-ketoisovaleric acid can reach 96.5 g/L, and the transformation rate is greater than 97%. By adopting the method of the disclosure, the cost can be greatly reduced, and the industrialization process of production of &#x3b1;-ketoisovaleric acid by an enzymatic transformation method is accelerated.

Preparation of L-amino acid deaminase mutant and application thereof

The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.

Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases

The present invention provides a recombinant strain, construction method thereof and a method for producing acid phosphatase using the recombinant strain. In the invention, the phosphatase gene is obtained fromby a molecular biology method, the constructed expression plasmid is transformed intoBL21 (DE3). The purified enzyme and whole cells were used for the conversion of ascorbic acid to ascorbic acid-2-phosphate. Ascorbic acid-2-phosphate can be efficiently produced by controlling the ratio of substrates. When the conversion reaction is performed at pH 4.5 under 40&#xb0; C. for 8 h, the output of ascorbic acid-2-phosphate reaches 54.8 g/L, the conversion is 42.9% and the space time yield is 6.9 g/L/h.

Method for preparing ascorbic acid-2-phosphate using a recombinant strain

Disclosed are dihydroindolone compounds which can modulate the activity of protein tyrosine kinases, a method for preparing the same, and pharmaceutical compositions comprising the same. Also disclosed are use of such compounds and pharmaceutical compositions thereof in the treatment and/or prophylaxis of protein tyrosine kinase associated diseases in an organism, particularly in the treatment and/or prophylaxis of tumors and fibroblast proliferation associated diseases.

Dihydroindolinone derivatives

Growing community of inventors

Jiangsu, China

Wei Song